Figure 3

Effect on Ba/F3-VEGFR2 cell proliferation when hVEGF is added together with pre-treatment (C1) or on-bevacizumab treatment serum. Effect on Ba/F3-VEGFR2 cell proliferation when pre-treatment patients’ serum or on-bevacizumab treatment serum (in 1 : 20 dilution) is co-incubated with hVEGF (1.25 ng ml⁻¹). Cell proliferation is quantified relatively to hVEGF 1.25 ng ml⁻¹. Cell proliferation is quantified relative to hVEGF 1.25 ng ml⁻¹. Patient samples 10, 16 and 21 were excluded for further analyses because of the inhibitory effects observed with pre-treatment serum. Data is shown as mean±s.d. of three independent experiments. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 (A). Correlation plot of bevacizumab concentration vs the inhibition of Ba/F3-VEGFR2 cell proliferation. Data points are the mean values±s.d. of three independent experiments (B for patients 1–8; C for patients 9–22). Correlation plot of platelet corrected on-treatment hVEGF concentration vs the inhibition of Ba/F3-VEGFR2 cell proliferation. Data points are the mean values±s.d. of three independent experiments (D for patients 1–8; E for patients 9–22).